A Yakima County resident exposed to infected dairy cattle has died of avian influenza. A third human case has also been confirmed as H5N1 spreads to 33 herds in the county.
|Articles|June 29, 2020
Contagion Live News Network: New COVID 19 Trial for Opaganib
Author(s)Contagion® Editorial Staff
A brief overview of our recent coverage.
Advertisement
Hello and welcome to Contagion — this is a brief overview of our recent coverage.
How have New York City intensive care units fared since the peak of the outbreak there? In an interview with Contagion, Bradley Sherman, MD, Medical Director and Chair of the Department of Medicine at Glen Cove Hospital, discussed the effect COVID-19 had on their ICU patient population—significantly more infected patients, significantly fewer non-COVID patients—and how it began to revert to the norm.
In other news, UK regulators approved the Phase 2/3 study of Opaganib against COVID-19. Opaganib is a first-in-class therapeutic under investigation in several indications. And lastly, while smallpox may not be in headlines today, the illness remains a threat.
For Contagion, I’m assistant editor Grant Gallagher. Thanks for tuning in.
Advertisement
Related to this article
Voceryq earned FDA accelerated approval for adults with RRP after 7 of 26 patients (27%) needed no surgery for 12 months in RRP-001; a confirmatory trial is required.
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
The latest CDC numbers show a 4.0% increase in measles cases from week-to-week, bringing the 2026 US total to 4588 confirmed cases. Ninety-six percent of cases are outbreak-associated.
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Oral zelicapavir cut time to complete RSV symptom resolution by up to 1 week in high-risk adults, but it did not meet its primary end point in a phase 2 trial.
Advertisement
Advertisement
Trending on Contagion Live
1
Nearly 30% of US Adults Report Misrepresenting Symptoms to Get Antibiotics
2
FDA Tentatively Approves First Generic Lenacapavir PrEP for 120 LMICs
3
Washington State Reports First US Avian Influenza Death of 2026
4
Postapproval Surveillance Confirms Ceftobiprole Activity Against MRSA
5